Do you want to read an article? Please log in or register.
Long-Term Benefit With First-Line Osimertinib Monotherapy in EGFR-Mutated Advanced NSCLC in the Era of Intensified First-Line Therapy
Lung, Respiratory and Thoracic Cancer
Related content
Lung, Respiratory and Thoracic Cancer
Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2
Lung Cancer
Planchard D, Jänne PA, Yang JC, Kobayashi K, Valdiviezo N, Fan Y, Kim TM, Gálvez ML, Nishino K, Biswas B, Feng PH, Sriuranpong V, Koubkova L, Pinto GDJ, Escriu C, Tran TV, Takahashi T, Nerón Y, Han JY, Figueroa A, Donachie V, Khullar A, Evans A, Albayaty M, Lee CK
doi: 10.1016/j.lungcan.2026.109588
CHICAGO 2026
Lung, Respiratory and Thoracic Cancer
CHRYSALIS-2: First-line amivantamab plus lazertinib demonstrates durable OS in atypical EGFR-mutated advanced NSCLC
Lung, Respiratory and Thoracic Cancer
First-line integration of Local Ablative Therapy (LAT) with EGFR Tyrosine Kinase Inhibitors (TKIs) in advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis
J Thorac Oncol
Brunetti L, Colella G, Di Fazio GR, La Cava G, Santo V, Pecci F, Rotow J, Bauman JR, Nassar AH, Adib E, Naqash AR, Tagliamento M, Ferrara R, Citarella F, Russano M, Ricciuti B, Faivre-Finn C, Hendriks LEL, Passaro A, Vincenzi B, Acker F, Derosa L, Planchard D, Aerts HJWL, Novello S, Passiglia F, Greco C, Ramella S, Cortellini A
doi: 10.1016/j.jtho.2026.103735
Lung, Respiratory and Thoracic Cancer
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study
Lung Cancer
Gomez-Randulfe I, Monaca F, Cantale O, Reale ML, Mrak L, Zullo L, Diaz SS, Bueno MZ, Maridueña Moreno MA, Davis C, Cox S, Lee D, Shah R, Geldart T, Baena J, Benitez JC, Rosario Garcia Campelo MA, Remon J, Planchard D, Galetta D, Tiseo M, Cortinovis D, Metro G, Bria E, Passiglia F, Novello S, Califano R
doi: 10.1016/j.lungcan.2025.108797
Lung, Respiratory and Thoracic Cancer
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis
Lung Cancer
Hayashi H, Cho BC, Kim YJ, Lee SH, Danchaivijitr P, Alip A, Xiong H, How SH, Chang GC, Yang JC, Yamanaka Y, Nahit Şendur MA, Prabhash K, Azuma K, Akawung A, Fennema E, Tang X, Shah S, Sethi S, Lu S
doi: 10.1016/j.lungcan.2026.109305
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Adv Ther
Girard N, Macouillard P, Byng D, Meng J, Coerts F, Hunter S, Struebing A, Xiong Y, Park S, Haq MI, Tymejczyk O, Chouaid C, Audigier-Valette C, Debieuvre D, Quantin X, Bosquet L, Pérol M
doi: 10.1007/s12325-025-03465-4
Lung, Respiratory and Thoracic Cancer
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC
Lung Cancer
Paz-Ares L, Veillon R, Majem M, Zhou C, Tang KJ, Kim SW, Richardson G, Girard N, Sanborn RE, Mansfield AS, Park K, Schuchard J, Diels J, Sermon J, Bhattacharya A, Lorenzini P, Wortman-Vayn H, Knoblauch RE, Agrawal T, Baig M, Ono A, Sabari JK
doi: 10.1016/j.lungcan.2025.108788
WCLC 2026
Lung, Respiratory and Thoracic Cancer
ADAURA: Adjuvant osimertinib provides OS benefit at eight years in patients with resected EGFR-mutated NSCLC
ESMO 2026
Lung, Respiratory and Thoracic Cancer